ArticleExperimental and therapeutic medicine2022
Article in Experimental and therapeutic medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy and Safety of Oral Lactobacillus Plantarum GUANKE (CGMCC NO.21720) in Enhancement of Antibody Level After SARS-CoV-2 Vaccination: A Prospective, Randomized, Double-blind, Placebo-Controlled Trial (Trial 1)
Efficacy and Safety of Oral Lactobacillus Plantarum GUANKE (CGMCC NO.21720) in Enhancement of Antibody Level After SARS-CoV-2 Vaccination: A Prospective, Randomized, Double-blind, Placebo-Controlled Trial (Trial 2)
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Effectiveness of probiotics on COVID-19 prevention and treatment against mild COVID-19 in outpatient care: A systematic review.Nutrition and health · 2026Pooled it
- Article
- Deciphering respiratory viral infections by harnessing organ-on-chip technology to explore the gut-lung axis.Open biology · 2025Review
- The relationship between gut and nasopharyngeal microbiome composition can predict the severity of COVID-19.eLife · 2025Observational
- Intestinal-pulmonary axis: a 'Force For Good' against respiratory viral infections.Frontiers in immunology · 2025Review
- The pediatric gut bacteriome and virome in response to SARS-CoV-2 infection.Frontiers in cellular and infection microbiology · 2024Article
- The extracellular polysaccharide inhibit porcine epidemic diarrhea virus with extract and gene editing Lacticaseibacillus.Microbial cell factories · 2023Article
- COVID-19 Therapeutic Potential of Natural Products.International journal of molecular sciences · 2023Review
- Mucosal immunization with lactiplantibacillus plantarum-displaying recombinant SARS-CoV-2 epitopes on the surface induces humoral and mucosal immune responses in mice.Microbial cell factories · 2023Article
- Observational
- Evaluation of the gut microbiome associated with COVID-19.Informatics in medicine unlocked · 2023Article
- Limited Impact of SARS-CoV-2 on the Human Naso-Oropharyngeal Microbiota in Hospitalized Patients.Microbiology spectrum · 2022Article
- Role of SARS-CoV-2-induced cytokine storm in multi-organ failure: Molecular pathways and potential therapeutic options.International immunopharmacology · 2022Review
- Gut Microbiota and COVID-19: Potential Implications for Disease Severity.Pathogens (Basel, Switzerland) · 2022Review
- Long-term implications of COVID-19 on bone health: pathophysiology and therapeutics.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2022Review
- Immunomodulatory Effects of Probiotics on COVID-19 Infection by Targeting the Gut-Lung Axis Microbial Cross-Talk.Microorganisms · 2022Review
- Pharmacological Efficacy of Probiotics in Respiratory Viral Infections: A Comprehensive Review.Journal of personalized medicine · 2022Review
- Probiotics, their action modality and the use of multi-omics in metamorphosis of commensal microbiota into target-based probiotics.Frontiers in nutrition · 2022Review
- Administration ofFrontiers in microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intestinal microbiota can indirectly modulate airway physiology and immunity through the gut-lung axis. Recent microbiome studies indicate that patients with coronavirus disease 2019 (COVID-19) exhibit a specific intestinal dysbiosis that is closely associated with the disease pathophysiology. Therefore, rebalancing the intestinal microbiome using probiotics may be effective for controlling COVID-19. However, the rationale for using probiotics in COVID-19 remains unclear. In the present study, an
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.